Autopsy report · NCT02405793

Meloxicam SoluMatrix® Capsules vs Meloxicam Tablets to Treat Osteoarthritis Pain

“Internal business decision not to move forward with study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Iroko Pharmaceuticals, LLC

Sponsor type

Industry

Conditions

Osteoarthritis

Interventions

Meloxicam Test Capsules; Meloxicam Test Capsules; Meloxicam Tablets

Participants

0

Trials that died the same way

• Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
  “Company decision not to start the study” (66% match in meaning)
• A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
  “Business decision to stop the study.” (66% match in meaning)
• Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
  “Decision was made to not go forward with the study” (64% match in meaning)
• The Impact of E-liquid Nicotine Content on Reinforcement in Current Smokers
  “Study team decided not to move forward with study” (64% match in meaning)
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
  “Amgen decided to discontinue study because of a business decision and not because of safety reasons” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.